HealthAxios Techabout 2 hours ago
Novo sues Eli Lilly over weight-loss drug ads
2 min read
Novo Nordisk sued Eli Lilly on Tuesday, accusing the rival of deceptive advertising in weight-loss drug marketing. Novo alleged Lilly's ads compare high-dosage GLP-1 treatments to lower dosages of Novo drugs using outdated studies. Lilly and Novo control the majority of the GLP-1 drug market.
Level
Hype check
Tap to vote and see what everyone thinks.
Summary by ByteBrief
